{"title":"Short-term respiratory outcome of mechanically ventilated preterm infants treated by dexmedetomidine: randomized controlled trial","authors":"M. Zedan, Maged Mostafa, E. Thabet, I. Nour","doi":"10.4103/ajop.ajop_42_20","DOIUrl":null,"url":null,"abstract":"Background The evidence of routine use of sedatives in mechanically ventilated preterm infants is not established because of adverse effects of commonly used drugs. Dexmedetomidine (DEX) is an emerging alternative. Objective To assess safety and efficacy of DEX use as a sedative in mechanically ventilated preterm neonates. Patients and methods A double-blind, randomized controlled trial was conducted on 40 preterm infants less than or equal to 32 weeks of gestation who required mechanical ventilation (MV) during the first 5 days of life. They were randomly assigned to receive DEX (0.1 μg/kg/h) during the first 5 days or placebo. Time to first extubation was our primary outcome, and secondary outcomes were plasma Krebs von den Lundgen-6 at seventh day, bronchopulmonary dysplasia, total duration of MV, total duration of oxygen supplementation, need for postnatal steroid, pain score, necrotizing enterocolitis, intraventricular hemorrhage, patent ductus arteriosus, need for positive inotropes, retinopathy of prematurity requiring intervention, days to reach 100 ml/kg enteral feeds, adverse effects of DEX, and mortality. Results A total of 40 neonates (20 in each group) were enrolled. DEX use was associated with earlier extubation of mechanically ventilated preterm infants (P=0.001) compared with placebo. Durations of respiratory support and MV were significantly shorter in DEX group compared with placebo. DEX therapy was associated with lower level of serum Krebs von den Lundgen-6 and Echelle de Douleur et d’Inconfort du Nouveau-né pain score compared with placebo. Patients in DEX group have less need to fentanyl dosing and low incidence of sepsis and intraventricular hemorrhage. There was no significant difference between groups regarding other secondary outcomes. There is no significant difference between groups regarding adverse effects. Conclusion We concluded that DEX has beneficial effect on short-term respiratory outcome in mechanically ventilated preterm infants without significant effect on neonatal mortality.","PeriodicalId":7866,"journal":{"name":"Alexandria Journal of Pediatrics","volume":"1 1","pages":"136 - 143"},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alexandria Journal of Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajop.ajop_42_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background The evidence of routine use of sedatives in mechanically ventilated preterm infants is not established because of adverse effects of commonly used drugs. Dexmedetomidine (DEX) is an emerging alternative. Objective To assess safety and efficacy of DEX use as a sedative in mechanically ventilated preterm neonates. Patients and methods A double-blind, randomized controlled trial was conducted on 40 preterm infants less than or equal to 32 weeks of gestation who required mechanical ventilation (MV) during the first 5 days of life. They were randomly assigned to receive DEX (0.1 μg/kg/h) during the first 5 days or placebo. Time to first extubation was our primary outcome, and secondary outcomes were plasma Krebs von den Lundgen-6 at seventh day, bronchopulmonary dysplasia, total duration of MV, total duration of oxygen supplementation, need for postnatal steroid, pain score, necrotizing enterocolitis, intraventricular hemorrhage, patent ductus arteriosus, need for positive inotropes, retinopathy of prematurity requiring intervention, days to reach 100 ml/kg enteral feeds, adverse effects of DEX, and mortality. Results A total of 40 neonates (20 in each group) were enrolled. DEX use was associated with earlier extubation of mechanically ventilated preterm infants (P=0.001) compared with placebo. Durations of respiratory support and MV were significantly shorter in DEX group compared with placebo. DEX therapy was associated with lower level of serum Krebs von den Lundgen-6 and Echelle de Douleur et d’Inconfort du Nouveau-né pain score compared with placebo. Patients in DEX group have less need to fentanyl dosing and low incidence of sepsis and intraventricular hemorrhage. There was no significant difference between groups regarding other secondary outcomes. There is no significant difference between groups regarding adverse effects. Conclusion We concluded that DEX has beneficial effect on short-term respiratory outcome in mechanically ventilated preterm infants without significant effect on neonatal mortality.
背景:由于常用药物的不良反应,机械通气早产儿常规使用镇静剂的证据尚未建立。右美托咪定(DEX)是一种新兴的替代品。目的评价DEX用于机械通气早产儿镇静的安全性和有效性。患者与方法:对40例出生后5天需要机械通气(MV)的小于或等于妊娠32周的早产儿进行了双盲、随机对照试验。随机分为前5天服用0.1 μg/kg/h的DEX组和安慰剂组。第一次拔管的时间是我们的主要终点,次要终点是第7天的血浆Krebs von den lunden -6、支气管肺发育不良、MV总持续时间、补充氧气总持续时间、产后类固醇的需求、疼痛评分、坏死性小肠结肠炎、脑室内出血、动脉导管未闭、正性肌力的需求、需要干预的早产儿视网膜病变、达到100 ml/kg肠内喂养的天数、DEX的不良反应和死亡率。结果共纳入40例新生儿,每组20例。与安慰剂相比,DEX的使用与机械通气早产儿早期拔管相关(P=0.001)。与安慰剂组相比,DEX组呼吸支持和MV持续时间明显缩短。与安慰剂相比,DEX治疗与血清Krebs von den Lundgen-6和Echelle de Douleur et d ' incomfort du nouveau - naux疼痛评分水平较低相关。DEX组患者对芬太尼剂量的需求较小,败血症和脑室内出血的发生率较低。在其他次要结果方面,两组间无显著差异。两组之间在不良反应方面没有显著差异。结论DEX对机械通气早产儿短期呼吸结局有改善作用,对新生儿死亡率无显著影响。